Armata Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the Annual Meeting of Shareholders held on June 12, 2025. The filing details the results of shareholder votes regarding director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
Shareholders approved the following matters at the Annual Meeting:
- Director Elections: Seven members were elected to the Board of Directors for one-year terms expiring in 2026. All candidates received significant majority support with minimal shares withheld.
- Executive Compensation: Shareholders approved, on a non-binding advisory basis, the compensation of named executive officers. The vote was 30,180,386 shares for, 75,804 against, and 31,922 abstaining.
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The vote was 31,471,009 shares for, 4,970 against, and 2,147 abstaining.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder meeting.
Key Facts for Investor Verification
- Verify the composition of the newly elected Board of Directors and their respective terms.
- Confirm the appointment of Ernst & Young LLP as the auditor for the fiscal year ending December 31, 2025.
- Note the high level of shareholder support for executive compensation (approximately 97.5% voted "for").
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K does not contain them.